Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04094766

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia Clinical Trial

Official title:
A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute B Lymphoblastic Leukemia

Clinical Trial Summary

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of dual specificity CD19 and CD22 CAR-T cells in patients with relapsed and refractory acute B lymphoblastic leukemia.

Clinical Trial Description

CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory acute B lymphoblastic leukemia. CD19 and CD22 are proteins usually expressed on the surface of the B leukemia cells. The dual specificity CAR enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22. ;

Study Design

Related Conditions & MeSH terms

  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Refractory B Acute Lymphoblastic Leukemia
  • Relapse B Acute Lymphoblastic Leukemia
Clinical Trial Details
NCT number NCT04094766
Study type Interventional
Source Second Affiliated Hospital of Xi'an Jiaotong University
Contact
Status Withdrawn
Phase Phase 1
Start date August 1, 2017
Completion date August 30, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03991884 - Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Phase 1
Active, not recruiting NCT02879695 - Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Phase 1
Recruiting NCT04723901 - Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Terminated NCT03103971 - huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Phase 1
Active, not recruiting NCT04681105 - Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Phase 1
Completed NCT03472573 - Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT03739814 - Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Phase 2
Withdrawn NCT04029038 - Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Phase 1/Phase 2
Recruiting NCT05418088 - Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Phase 1
Terminated NCT03579888 - CD19-Specific T Cells Post AlloSCT Phase 1
Recruiting NCT02981628 - Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Phase 2
Terminated NCT02420717 - Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Phase 2
Withdrawn NCT03851081 - Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT04556084 - Blinatumomab Bridging Therapy Phase 2
Recruiting NCT05032183 - Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Phase 1/Phase 2
Recruiting NCT01371630 - Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT03698552 - ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Withdrawn NCT05320380 - A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Phase 1/Phase 2
Recruiting NCT03808610 - Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Terminated NCT03518112 - Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia Phase 2